Article
Tacrolimus dosing in liver transplant recipients using phenotypic personalized medicine: A phase 2 randomized clinical trial.
Nature communications - 16 May 2025
Khong Jeffrey, Lee Megan, Warren Curtis, Kim Un Bi, Duarte Sergio, Andreoni Kenneth A, Shrestha Sunaina, Johnson Mark W, Battula Narendra R, McKimmy Danielle M, Beduschi Thiago, Lee Ji-Hyun, Li Derek M, Ho Chih-Ming, Zarrinpar Ali
Abstract excerpt
Tacrolimus is the most commonly used immunosuppression drug after solid organ transplantation; however, its dosing is challenging due to substantial inter-individual variability, often resulting in blood levels that deviate from the target therapeutic range. We explored whether a dynamically customized, phenotypic-outcome-guided drug dosing method could improve maintenance of drug trough levels within...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.